NKGen Biotech Corp (NKGN) - מזומנים למניה אחת

The historical cash per share level provided by the GURU.Markets platform shows that the latest figure is 0.00. NKGen Biotech, Inc. (NKGN) is implementing laboratory automation to accelerate Alzheimer's therapy testing. Patent ownership ensures the global scaling of treatment methods and high profitability. A scientific approach and generous stock options make NKGen Biotech, Inc. (NKGN) an attractive hub for leading neurobiologists.
פילוחים אנליטיים של חברת NKGen Biotech, Inc.

The development of the SNK01 platform for Alzheimer's therapy requires significant investment before achieving pricing power. This metric is calculated by dividing total liquid assets by the number of shares outstanding. It determines the internal financial buffer that protects the business from market volatility. Excess funds may signal inefficient capital management. By analyzing the cash per share for NKGen Biotech, Inc. (NKGN) on GURU.Markets, an investor assesses the resilience of NKGen Biotech, Inc. (NKGN) to external shocks.